Study wrapper · #888
Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk.
Inia JA, Droog S, Snabel J, et al. Diabetes & metabolism journal. 2026.
DOI: 10.4093/dmj.2025.1060PubMed: 42449565
Editor's note
This mouse study found semaglutide reduced both fat and lean mass, and that adding exercise partially preserved muscle while improving metabolic and vascular outcomes. Semaglutide is a genuine subject and the lean-mass finding is a relevant caveat for the drug class. Evidence is preclinical, so conclusions should not be extrapolated directly to people.
Plain-language abstract
In obese mice, semaglutide reduced fat but also lean mass, while combining it with exercise preserved more muscle and improved liver and vascular measures.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026